

## Contents

Preface XIX

List of Contributors XXI

### Part I Biochemistry and Biophysics 1

#### 1 Investigations on Fluorine-Labeled Ribonucleic Acids by $^{19}\text{F}$ NMR Spectroscopy 3

*Christoph Kreutz and Ronald Micura*

- 1.1 Introduction 3
- 1.1.1 NMR Spectroscopic Properties of the  $^{19}\text{F}$  Nucleus 3
  - 1.1.1.1 General NMR Spectroscopic Properties 3
  - 1.1.1.2  $^{19}\text{F}$  versus  $^1\text{H}$  NMR Spectroscopy 3
  - 1.1.1.3 Factors Affecting the  $^{19}\text{F}$  Chemical Shift in Biomolecules 5
  - 1.1.1.4 Fluorine Relaxation in Biological Systems 6
  - 1.1.1.5 Solvent-Induced Isotope Shifts of  $^{19}\text{F}$  NMR Resonances 7
- 1.1.2  $^{19}\text{F}$  NMR Spectroscopy of Proteins 7
  - 1.1.2.1 Incorporation of Fluorinated Amino Acids into Proteins 7
  - 1.1.2.2  $^{19}\text{F}$  NMR Spectroscopic Studies of Proteins 8
- 1.2  $^{19}\text{F}$  NMR Spectroscopy of Nucleic Acids 13
  - 1.2.1 Nucleic Acids with Fluorinated Nucleobases 14
    - 1.2.1.1 Transfer RNAs 14
    - 1.2.1.2 *HhaI* Methyltransferase in Complex with DNA Duplexes 14
    - 1.2.1.3 Minimal Hammerhead Ribozyme 15
    - 1.2.1.4 HIV TAR RNA 17
  - 1.2.2 Nucleic Acids with Fluorinated Ribose Units 19
    - 1.2.2.1 *R1inv* RNA 19
    - 1.2.2.2 RNA Secondary Structure Equilibria 21
    - 1.2.2.3 RNA Ligand Binding 22
- 1.2.3 Influence of Fluorine Modifications on Nucleic Acid Structure 22
- 1.3 Conclusions 24
- References 24

<b>2</b>	<b>8-Oxo-7,8-Dihydro-2'-Deoxyguanosine: A Major DNA Oxidation Product</b>	<b>29</b>
	<i>Jean Cadet and Paolo Di Mascio</i>	
2.1	Introduction	29
2.2	Formation of 8-Oxo-7,8-Dihydroguanine	30
2.2.1	Single Lesion	30
2.2.1.1	·OH Radical	31
2.2.1.2	One-Electron Oxidation	31
2.2.1.3	Singlet Oxygen	32
2.2.2	Tandem Lesions	34
2.3	Reactivity of 8-Oxo-7,8-Dihydro-2'-Deoxyguanosine	35
2.3.1	One-Electron Oxidation	35
2.3.1.1	Secondary Oxidation Products	36
2.3.1.2	DNA-Protein Crosslinks	37
2.3.2	Singlet Oxygen	37
2.3.2.1	Nucleoside	37
2.3.2.2	Oligonucleotide	38
2.4	Formation of 8-Oxo-7,8-Dihydro-2'-Deoxyguanosine in Cellular DNA	39
2.4.1	Methods of Measurement	39
2.4.1.1	HPLC Methods (HPLC-ECD and HPLC-MS/MS)	39
2.4.1.2	Enzymic Assays	40
2.4.2	Indirect Effects of Ionizing Radiation (·OH Radical)	41
2.4.3	High-Intensity UV Laser Irradiation (One-Electron Oxidation)	41
2.4.4	UVA Photosensitization ( <sup>1</sup> O <sub>2</sub> )	42
2.5	Synthesis of 8-OxodGuo and Insertion into Oligonucleotides	42
2.6	Conclusions	43
	References	44
<b>3</b>	<b>Modified DNA Bases: Probing Base-Pair Recognition by Polymerases</b>	<b>49</b>
	<i>Eric T. Kool</i>	
3.1	Introduction	49
3.1.1	The Importance of Understanding DNA Polymerases	49
3.1.2	The Utility of Modified Nucleobases in Probing Mechanisms	50
3.1.3	The Scope of this Chapter	50
3.2	Basic Principles and Methods in Replication	51
3.2.1	The Chemistry of Polymerases	51
3.2.2	Different Classes of Polymerases	51
3.2.3	Methods Used in Polymerase Studies	52
3.3	Alternative Hydrogen-Bonding Schemes	53
3.3.1	Thioguanine-Pyridone	53
3.3.2	Benner Hydrogen-Bonding Variants	54
3.4	Non-Polar Nucleoside Isosteres	56
3.4.1	The Concept of Nucleobase Isosteres	56

3.4.2	Synthesis, Structure, and Physical Properties	56
3.4.3	Base-Pairing Properties	57
3.4.4	Polymerase Behavior	58
3.4.5	Other Classes of Polymerases	59
3.4.6	Summary of Watson–Crick H-Bonding Effects in Polymerase Active Sites	60
3.5	Non-Polar Steric Probes	60
3.5.1	Isomers of Hydrocarbons Illustrate Hydrophobic “Packing” Effects	60
3.5.2	Systematic Size Variants	62
3.5.3	Systematic Shape Variants	63
3.6	Minor Groove Hydrogen Bonds in Polymerases	64
3.6.1	Base Analogues Testing Minor Groove Interactions	64
3.7	Other Non-Polar Bases and Pairs	65
3.7.1	The Quest for New Base Pairs	65
3.7.2	A Broad Variety of Heterocycles and Hydrocarbons	66
3.7.3	Benzimidazoles Continue the Debate on Steric Effects	67
3.7.4	New Pairs of Hirao and Yokoyama	67
3.8	Replication of Designed Bases in Living Cells	68
3.8.1	Effects of Hydrogen Bonding in <i>E. coli</i>	68
3.8.2	Effects of Nucleobase Size in <i>E. coli</i>	69
3.9	Conclusions and Future Prospects	70
3.9.1	What We Know About Replication	70
3.9.2	And What Remains Unknown	71
3.9.3	Future Directions	71
	References	71
<b>4</b>	<b>2'-Deoxyribose-Modified Nucleoside Triphosphates and their Recognition by DNA Polymerases</b>	<b>75</b>
	<i>Karl-Heinz Jung and Andreas Marx</i>	
4.1	Introduction	75
4.2	Modified Nucleotides as Alternative Building Blocks to Natural Nucleic Acids	76
4.2.1	Introduction	76
4.2.2	Nucleotides with Downsized Residues: $\alpha$ -L-Threose-Derived Nucleotides	76
4.2.2.1	Introduction	76
4.2.2.2	Synthesis	77
4.2.2.3	DNA Polymerase Studies	80
4.2.3	Nucleotides with Downsized Residues: Glycerol-Derived Nucleotides	80
4.2.3.1	Introduction	80
4.2.3.2	Synthesis	81
4.2.3.3	DNA Polymerase Studies	82
4.2.4	Nucleotides with Expanded Sugar Residues: 1,5-Anhydrohexitol Nucleotides	82

4.2.4.1	Introduction	82
4.2.4.2	Synthesis	83
4.2.4.3	Functional DNA Polymerase Studies	85
4.2.5	Nucleotides with Expanded Sugar Residues: Cyclohexenyl Nucleotides	85
4.2.5.1	Introduction	85
4.2.5.2	Synthesis	86
4.2.5.3	DNA Polymerase Studies	88
4.3	DNA Polymerase Selectivity: 4'-C-Modified Nucleotides	89
4.3.1	Introduction	89
4.3.2	Design and Synthesis	90
4.3.3	DNA Polymerase Studies	91
4.4	Concluding Remarks	93
	References	94
<b>5</b>	<b>Pyrimidine Dimers: UV-Induced DNA Damage</b>	<b>97</b>
	<i>Shigenori Iwai</i>	
5.1	Introduction	97
5.2	Formation of Pyrimidine Dimers	98
5.2.1	Cyclobutane Pyrimidine Dimers	98
5.2.2	The (6-4) Photoproducts and their Dewar Valence Isomers	101
5.2.3	Other UV Lesions	101
5.3	Chemical Synthesis of Oligonucleotides Containing Pyrimidine Dimers	103
5.3.1	Oligonucleotides Containing a CPD	103
5.3.2	Oligonucleotides Containing the (6-4) or Dewar Photoproduct	105
5.4	Structure and Mutagenesis of Pyrimidine Dimer-Containing DNA	109
5.4.1	Tertiary Structures of Pyrimidine Dimer-Containing Duplexes	109
5.4.2	Base-Pair Formation by Pyrimidine Dimers	111
5.4.3	Mutations Induced by Pyrimidine Dimers	112
5.5	Repair of Pyrimidine Dimers in Cells	116
5.5.1	T4 Endonuclease V	116
5.5.2	Photolyases	118
5.5.3	Nucleotide Excision Repair (NER)	119
5.5.4	UV Damage Endonuclease (UVDE)	121
5.6	Bypass of Pyrimidine Dimers by DNA Polymerases	122
	References	124
<b>6</b>	<b>Locked Nucleic Acids: Properties, Applications, and Perspectives</b>	<b>133</b>
	<i>Poul Nielsen and Jesper Wengel</i>	
6.1	Introduction	133
6.2	LNA in High-Affinity Hybridization: Designing Sequences	135
6.3	Structural Studies	139
6.4	Analogues of LNA and their Structural Impact	140
6.5	LNA as Potential Therapeutics	143
6.6	LNA-Probes	147

6.7	Concluding Remarks	148
	References	149
<b>7</b>	<b>Synthesis and Properties of Oligonucleotides Incorporating Modified Nucleobases Capable of Watson–Crick-Type Base-Pair Formation</b>	<b>153</b>
	<i>Mitsuo Sekine, Akio Ohkubo, Itaru Okamoto, and Kohji Seio</i>	
7.1	Introduction	153
7.2	Natural, Enzyme-Assisted Sophisticated Devices for Maintaining Correct Base Recognition of Canonical Nucleobases	154
7.3	Synthesis and Properties of Oligodeoxynucleotides Incorporating 4- <i>N</i> -Acylated Cytosine Derivatives	155
7.4	Base-Recognition Ability of 4- <i>N</i> -Alkoxy-carbonylcytosine Derivatives	157
7.5	Synthesis and Properties of Oligonucleotides Incorporating 4- <i>N</i> -Carbamoylcytosine Derivatives	159
7.6	2-Thiouracil as an Improved Nucleobase in Place of Thymine	160
7.7	Modified Adenine Bases Capable of Recognizing the Thymine Base	161
7.8	Design of Modified Guanine Bases Capable of Recognizing Cytosine	165
7.9	Conclusions	168
	References	168
<b>8</b>	<b>The Properties of 4'-Thionucleosides</b>	<b>173</b>
	<i>Masataka Yokoyama</i>	
8.1	Introduction	173
8.2	Synthesis of 4'-Thionucleosides	173
8.3	Synthesis of Isothionucleosides	195
8.4	Synthesis of L-Thionucleosides	196
8.5	Synthesis of Thioxonucleosides	198
8.6	Synthesis of Miscellaneous Thionucleosides	205
8.7	Biological Activity of Thionucleosides	210
8.8	Conclusions	219
	References	219
<b>9</b>	<b>S-Adenosyl-L-methionine and Related Compounds</b>	<b>223</b>
	<i>Christian Dalhoff and Elmar Weinhold</i>	
9.1	Introduction	223
9.2	The Biochemistry of AdoMet	224
9.2.1	AdoMet as a Methyl and Methylene Group Donor	224
9.2.2	AdoMet as an Aminocarboxypropyl Group Donor	227
9.2.3	AdoMet as an Adenosyl Group Donor	228
9.2.4	AdoMet as a Ribosyl Group Donor	228
9.2.5	AdoMet as a Radical Source	229
9.2.6	AdoMet as an Amino Group Donor	229
9.2.7	AdoMet-Dependent Riboswitches	230
9.2.8	The Biosynthesis and Metabolism of AdoMet	230

9.3	The Chemistry and Biochemistry of Modified AdoMet	231
9.3.1	Synthetic Approaches to AdoMet Analogues	231
9.3.2	Isotope-Labeled AdoMet	232
9.3.3	Selenium and Tellurium Analogues of AdoMet	234
9.3.4	Sulfoxide and Sulfone Analogues of AdoMet	236
9.3.5	Sinefungin	237
9.3.6	Nitrogen Analogues of AdoMet	237
9.3.7	Aziridine Analogues of AdoMet	238
9.3.8	AdoMet Analogues with Methyl Group Replacements	238
9.4	AdoMet as a Pharmaceutical	240
9.5	Concluding Remarks	241
	References	242
<b>Part II</b>	<b>Biotechnology</b>	<b>249</b>
<b>10</b>	<b>5-Substituted Nucleosides in Biochemistry and Biotechnology</b>	<b>251</b>
	<i>Mohammad Ahmadian and Donald E. Bergstrom</i>	
10.1	Introduction	251
10.2	Synthesis	252
10.2.1	Organopalladium Coupling Reactions	252
10.2.2	Strategies for Post-Oligonucleotide-Synthesis Modification through Pyrimidine C-5	253
10.3	Incorporation of C-5-Substituted Pyrimidine Nucleotides into Nucleic Acids through Modified Nucleotide 5'-Triphosphates	255
10.3.1	The Early Studies	255
10.3.2	Incorporation of Diverse Functionality into DNA	257
10.3.3	T7 RNA Polymerase-Mediated Synthesis of Modified RNA	262
10.3.4	Incorporation of C-5-Appended Fluorophores	262
10.4	C-5 Substituents that Stabilize DNA Duplexes	264
10.5	Photochemistry	269
10.6	Conclusions	271
	References	271
<b>11</b>	<b>Universal Base Analogues and their Applications to Biotechnology</b>	<b>277</b>
	<i>Kathleen Too and David Loakes</i>	
11.1	Introduction	277
11.2	General Methods of Synthesis	278
11.3	Properties of Universal Bases	282
11.4	Structure, Stacking, and Stabilization	283
11.5	Hydrogen-Bonding Universal Base Analogues	287
11.6	Applications of Universal Base Analogues	290
11.7	Triphosphate Derivatives	295
11.8	Therapeutic Applications	298
	References	300

**Part III Medicinal Chemistry 305****12 The Properties of Locked Methanocarba Nucleosides in Biochemistry, Biotechnology, and Medicinal Chemistry 307***Victor E. Marquez*

- 12.1 Introduction 307
- 12.2 Structural Representation 308
  - 12.2.1 The Bicyclo[3.1.0]hexane Template 308
  - 12.2.2 Pseudoboat versus Pseudochair Conformations 309
- 12.3 Synthesis of Locked Nucleosides 309
  - 12.3.1 North (*N*) Conformer Mimics 311
    - 12.3.1.1 Dideoxyribonucleoside Analogues 311
    - 12.3.1.2 2'-Deoxyribonucleoside Analogues 312
    - 12.3.1.3 Ribonucleoside Analogues 318
  - 12.3.2 South (*S*) Conformer Mimics 320
    - 12.3.2.1 2'-Deoxyribonucleoside Analogues 320
    - 12.3.2.2 Ribonucleoside Analogues 321
  - 12.3.3 Synthesis of *N*- and *S*-Methanocarba AZT Analogues 323
  - 12.3.4 Synthesis of Bicyclo[3.1.0]hexene Nucleosides 324
  - 12.3.5 Reshuffling of Groups on a Bicyclo[3.1.0]hexane Template 326
  - 12.3.6 Bicyclo[3.1.0]hexane Pseudosugars as Surrogates of Abasic Nucleosides 327
- 12.4 Synthesis of Oligodeoxynucleotides (ODNs) Containing Locked Nucleosides 328
  - 12.4.1 The Dickerson–Drew (DD) Dodecamer 330
- 12.5 Molecular Targets, Ligand Properties, and Binding Modes 331
  - 12.5.1 Kinases and Polymerases 331
  - 12.5.2 HIV Reverse Transcriptase 335
  - 12.5.3 DNA Methyltransferase 337
- 12.6 Concluding Remarks 339
- References 339

**13 Synthesis, Chemical Properties and Biological Activities of Cyclic Bis(3'-5')diguanlylic Acid (*c*-di-GMP) and its Analogues 343***Mamoru Hyodo and Yoshihiro Hayakawa*

- 13.1 Introduction 343
- 13.2 Synthesis of *c*-di-GMP and its Analogues 345
  - 13.2.1 Synthesis of *c*-di-GMP 345
  - 13.2.2 Synthesis of Artificial Analogues of *c*-di-GMP 347
- 13.3 Chemical Properties of *c*-di-GMP and its Analogues 348
  - 13.3.1 Stability and Chemical Properties of *c*-di-GMP under Acidic, Basic, and Physiological Conditions 348
  - 13.3.2 Polymorphism of *c*-di-GMP in Aqueous Solutions 349

13.4	Bioactivities of <i>c</i> -di-GMP and its Analogues	351
13.4.1	Activity of <i>c</i> -di-GMP on Biofilm Formation	352
13.4.1.1	Inhibition of Biofilm Formation and Prevention of Bacterial Infection of <i>S. aureus in vitro</i>	352
13.4.1.2	Activity as an Immunostimulatory Molecule	353
13.4.1.3	Activity on Biofilm Formation and Virulence Emergence of <i>P. aeruginosa</i>	357
13.4.2	Inhibition of Proliferation of Human Colon Cancer Cells with <i>c</i> -di-GMP	357
13.4.3	Biological Activity of <i>c</i> -dGpGp	358
13.5	Conclusions	359
	References	361
<b>14</b>	<b>Siderophore Biosynthesis Inhibitors</b>	<b>365</b>
	<i>Courtney C. Aldrich and Ravindranadh V. Somu</i>	
14.1	Introduction	365
14.2	Synthesis, Physico-Chemical Properties, Metabolism, Mechanism of Action, and Biological Activity	365
14.2.1	Synthesis	365
14.2.2	Physico-Chemical Properties	366
14.2.3	Metabolism	367
14.2.4	Toxicity	367
14.2.5	Biochemical Target	368
14.2.6	Mechanism of Action	369
14.2.7	Biological Activity	369
14.3	Background of Siderophores: Molecular Target and Rationale for Inhibitor Design	370
14.4	Ligand Properties/Binding Mode	374
14.4.1	Nature of the Linker	375
14.4.2	Importance of the Aryl Ring	379
14.4.3	Role of the Ribose	382
14.4.4	Impact of the Nucleobase	385
14.5	Conclusions	388
	References	388
<b>15</b>	<b>Synthesis and Biological Activity of Selected Carbocyclic Nucleosides</b>	<b>393</b>
	<i>Adam Mieczkowski and Luigi A. Agrofoglio</i>	
15.1	Introduction	393
15.2	A-5021, Synguanol, and Cyclopropane Derivatives	395
15.3	Lobucavir and Cyclobutane Nucleoside Derivatives	398
15.4	Carbovir and 2',3'-Unsaturated Nucleoside Derivatives	405
15.5	Locked Nucleosides	413
15.6	Conclusions	420
	References	420

- 16**      **4'-C-Ethynyl-2'-Deoxynucleosides** 425  
*Hiroshi Ohrai*
- 16.1      Introduction 425
- 16.2      Murine Toxicity of Purine 4'EdNs 426
- 16.3      4'EdA Derivatives Stable to Adenosine Deaminase, and their Biological Properties 427
- 16.4      4'-C-Ethynylnucleosides without 3'-OH 429
- 16.4.1    2',3'-Dideoxy-4'-C-ethynylnucleoside 429
- 16.4.2    2',3'-Didehydrideoxy-4'-C-ethynylnucleosides 429
- 16.4.3    Carbocyclic and Other Heterocyclic Analogues of 4'-C-ethynylnucleoside 431
- References 431
- 17**      **Modified Nucleosides as Selective Modulators of Adenosine Receptors for Therapeutic Use** 433  
*Kenneth A. Jacobson, Bhalchandra V. Joshi, Ben Wang, Athena Klutz, Yoonkyung Kim, Andrei A. Ivanov, Artem Melman, and Zhan-Guo Gao*
- 17.1      Introduction 433
- 17.2      Molecular Targets and Binding Modes 434
- 17.3      AR Agonists as Clinical Candidates 434
- 17.3.1    Modified Nucleosides as A<sub>1</sub> AR Agonists 435
- 17.3.2    Modified Nucleosides as A<sub>2A</sub> AR Agonists 437
- 17.3.3    Modified Nucleosides as A<sub>2B</sub> AR Agonists 439
- 17.3.4    Modified nucleosides as A<sub>3</sub> AR Ligands 441
- 17.4      Summary 444
- References 444
- 18**      **The Design of Forodesine HCl and Other Purine Nucleoside Phosphorylase Inhibitors** 451  
*Philip E. Morris and Vivekanand P. Kamath*
- 18.1      Introduction 451
- 18.2      Purine Nucleoside Phosphorylase Enzyme Structure 452
- 18.2.1    Purine-Binding Site 453
- 18.2.2    Phosphate-Binding Site 454
- 18.2.3    Sugar-Binding Site 454
- 18.3      First-Generation PNP Inhibitors: Substrate Analogues 454
- 18.3.1    Chemistry of First-Generation PNP Inhibitors 458
- 18.4      Second-Generation PNP Inhibitors: Transition-State Inhibitors 460
- 18.4.1    Chemistry of Second-Generation PNP Inhibitors 461
- 18.4.2    Convergent Synthesis of Forodesine HCl 463
- 18.5      Third-Generation PNP Inhibitors: Transition-State Inhibitors 467
- 18.5.1    Chemistry of BCX-4208 467
- References 469

<b>19</b>	<b>Formycins and their Analogues: Purine Nucleoside Phosphorylase Inhibitors and their Potential Application in Immunosuppression and Cancer</b> 473
	<i>Agnieszka Bzowska</i>
19.1	Introduction 473
19.2	Chemical Structure of Formycins and their Analogues 475
19.2.1	Formycin A and B, Oxofornycin B 475
19.2.2	Structural Modifications of Formycins 476
19.2.2.1	N-Methyl and N-Substituted Analogues 476
19.2.2.2	Other Base-Modified Analogues 478
19.2.2.3	Sugar-Modified Analogues 478
19.2.3	Formycin Phosphates and Polyformycin Phosphates 478
19.3	Spectral Properties of Formycins 479
19.4	Sources of Formycins 483
19.4.1	Natural Sources and Biosynthesis 483
19.4.2	Synthesis 483
19.5	The Biological Activity of Formycins: A Brief Summary 485
19.6	Formycins and Analogues as Purine Nucleoside Phosphorylase Inhibitors 488
19.6.1	Molecular Target of Formycins: Purine Nucleoside Phosphorylase (PNP) 488
19.6.2	Formycins and Analogues in Studies of the Molecular Mechanism of Catalysis: The 3-D Structure of PNPs 489
19.6.2.1	Low-Molecular-Mass PNPs 490
19.6.2.2	High-Molecular-Mass PNPs 492
19.6.3	PNP Deficiency and the Potential Role of PNP Inhibitors 495
19.6.4	Formycins and Analogues as Inhibitors of Mammalian PNPs 496
19.7	Formycins as Inhibitors of Parasitic PNPs and Hydrolases 500
19.8	Actual and Potential Applications of Formycins 501
19.8.1	Formycin and Analogues in Assays of Enzyme Activity 501
19.8.2	Formycin and Analogues as Protein Ligands for X-Ray Structural Studies 502
19.8.3	Formycins and Analogues as Molecular Probes 502
19.8.4	Formycins as Ligands in Affinity Chromatography 503
19.8.5	Formycin B as a Tool to Study Nucleoside Transport 504
	References 504
<b>20</b>	<b>1-(3-C-Ethynyl-<math>\beta</math>-D-ribo-pentofuranosyl)cytosine (ECyd)</b> 511
	<i>Akira Matsuda</i>
20.1	Introduction 511
20.2	Synthesis of ECyd and its Analogues 511
20.3	Cytotoxic Activity and Structure–Activity Relationships of ECyd Analogues <i>In Vitro</i> , and <i>In Vitro</i> Antitumor Activity 513
20.4	Structural Features of ECyd and 4'-Thio-ECyd 513
20.5	Metabolism and Mechanism of Action 517

20.6	An Apoptotic Pathway Involving the Action of ECyd	519
20.7	Combination of ECyd with Low-Dose X-Irradiation	519
20.8	ECyd is Effective against Gemcitabine-Resistant Human Pancreatic Cancer Cells	520
20.9	Conclusions	521
	References	521
<b>21</b>	<b>Syntheses and Biological Activity of Neplanocin and Analogues</b>	<b>525</b>
	<i>Dilip K. Tosh, Hea Ok Kim, Shantanu Pal, Jeong A. Lee, and Lak Shin Jeong</i>	
21.1	Introduction	525
21.2	New Methodologies in the Synthesis of Neplanocin A	527
21.3	Modifications on Neplanocin A and Aristeromycin	532
21.3.1	C2' Modification	533
21.3.2	C3' Modification	536
21.3.3	C4' Modification	538
21.3.4	C5' Modification	540
21.3.5	C6' Modification	550
21.3.6	Base Modification	552
21.3.7	Miscellaneous	559
21.4	Conclusions	563
	References	563
<b>22</b>	<b>Clitocine and Its Analogues</b>	<b>567</b>
	<i>Hyunik Shin and Changhee Min</i>	
22.1	Clitocine: Isolation, Synthesis, and Biological Activity	567
22.1.1	Isolation	567
22.1.2	Synthesis	567
22.1.3	Biological Activity	569
22.2	Clitocine Analogues	571
22.2.1	Aglycone Modifications	571
22.2.2	Carbocyclic Analogues	573
22.2.3	Acylic Analogues	576
22.2.4	5'-Amino Analogues	578
	References	583
<b>Part IV</b>	<b>Antitumorals and Antivirals</b>	<b>585</b>
<b>23</b>	<b>Capecitabine Preclinical Studies: From Discovery to Translational Research</b>	<b>587</b>
	<i>Hideo Ishitsuka and Nobuo Shimma</i>	
23.1	Introduction	587
23.2	Drug Design and Discovery of Capecitabine	588
23.2.1	5'-DFUR as a Lead Compound of Capecitabine	588

23.2.2	5'-DFCR Derivatives	589
23.2.3	N <sup>4</sup> -Acyl-5'-DFCR Derivatives	589
23.2.4	N <sup>4</sup> -Alkoxy carbonyl-5'-DFCR Derivatives	590
23.3	Preclinical Studies	590
23.3.1	Tumor-Selective Delivery of the Active 5-FU	590
23.3.2	Anti-Tumor Activities	592
23.3.3	Dose Fractionation and Schedule	592
23.3.4	Safety (Dose Range and Mild Myelotoxicity)	593
23.4	Translational Research for Optimizing Capecitabine Efficacy	593
23.4.1	Factors that Influence Capecitabine Efficacy	593
23.4.2	Combination Therapy with Rational Partners	594
23.4.2.1	Combination with TP Up-Regulators	594
23.4.2.2	Combination with DPD Down-Regulators	594
23.4.3	Personalized Therapy of Rational Patient Populations	596
23.5	Conclusions	597
	References	598
<b>24</b>	<b>Tenofovir and Adefovir as Antiviral Agents</b>	<b>601</b>
	<i>Tomas Cihlar, William E. Delaney IV, and Richard Mackman</i>	
24.1	Introduction	601
24.2	Synthesis	602
24.2.1	Adefovir and Adefovir Dipivoxil	603
24.2.2	Tenofovir and Tenofovir Disoproxil Fumarate	605
24.3	Mechanism of Action	606
24.3.1	Membrane Transport and Intracellular Metabolism	606
24.3.2	Inhibition of Viral Polymerases	608
24.3.3	Spectrum of Antiviral Activity	609
24.4	Activity in Animal Models	612
24.4.1	Models for Retroviral Infections	612
24.4.2	Models for Hepadnavirus Infections	613
24.4.3	Herpes Models	614
24.5	Clinical Experience	614
24.5.1	Tenofovir Disoproxil Fumarate (Viread <sup>®</sup> )	614
24.5.2	Adefovir Dipivoxil (Hepsera <sup>®</sup> )	616
24.6	Drug Resistance	618
24.6.1	HIV Resistance	618
24.6.2	HBV Resistance	619
24.7	Novel Antiviral Nucleotides and Nucleotide Prodrugs	619
24.8	Conclusions	621
	References	622

<b>25</b>	<b>Clofarabine: From Design to Approval</b>	<b>631</b>
	<i>John A. Secrist III, Jaideep V. Thottassery, and William B. Parker</i>	
25.1	Introduction	631
25.2	Clofarabine: The Background	632
25.3	The Beginnings	632
25.4	The Next Generation of Compounds	635
25.5	Mechanism of Action of Clofarabine	639
25.5.1	Transport and Metabolism to Active Metabolites	639
25.5.2	Inhibition of DNA Synthesis	640
25.5.3	Induction of Apoptosis	641
25.5.4	Activity against Non-Proliferating Cancer Cells	642
25.6	Clofarabine to the Clinic	643
25.6.1	Clinical Trials and Approval	643
25.7	Summary and Comments	644
	References	644
	<b>Index</b>	<b>647</b>

